<DOC>
	<DOCNO>NCT00043134</DOCNO>
	<brief_summary>RATIONALE : Decitabine may help myelodysplasia cell develop normal stem cell . It yet know decitabine effective standard supportive care treat myelodysplastic syndrome . PURPOSE : Randomized phase III trial compare effectiveness low-dose decitabine standard supportive care treat old patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Low-Dose Decitabine Compared With Standard Supportive Care Treating Older Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy low-dose decitabine v standard supportive care , term overall survival , elderly patient myelodysplastic syndrome . - Compare response rate progression-free survival patient treat regimen . - Determine toxicity decitabine patient . - Assess duration hospitalization number blood transfusion patient treat regimen . - Assess quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord cytogenetic risk factor ( good v poor v intermediate v unknown ) , disease ( primary myelodysplastic syndrome ( MDS ) vs secondary MDS ) , participate center . Patients successful cytogenetic exam also stratify accord overall International Prognostic Scoring System score ( intermediate 1 vs intermediate 2 v high risk ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive decitabine IV 4 hour every 8 hour 3 day . Treatment repeat every 6 week 4-8 course absence disease progression unacceptable toxicity . - Arm II : Patients receive standard supportive care . Quality life assess baseline , every 6 week therapy , every 2 month 1 year , every 3 month thereafter . Patients follow every 2 month 1 year every 3 month thereafter . PROJECTED ACCRUAL : A total 220 patient ( 110 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary secondary myelodysplastic syndrome ( MDS ) Any FAB WHO criteria cellular type allow Bone marrow blast count aspiration biopsy 1 following : No 10 % poor cytogenetic risk factor ( defined numerical structural abnormality chromosome 7 and/or complex abnormality ) 1120 % 2130 % patient acute myeloid leukemia ( AML ) secondary MDS ( i.e. , refractory anemia excess blast transformation FAB classification ) Patients fail cytogenetic exam allow provide bone marrow blast least 5 % and/or 23 cytopenias present No rapid progression towards fullblown AML No blast crisis chronic myeloid leukemia No ( 8 ; 21 ) alone combination abnormality Ineligible intensive chemotherapy ( e.g. , cytarabine anthracycline ) PATIENT CHARACTERISTICS : Age 60 Performance status WHO 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) Hepatitis B surface antigen negative Renal Creatinine less 1.5 time ULN Cardiovascular No severe cardiovascular disease No arrhythmia require chronic treatment No congestive heart failure No New York Heart Association class III IV heart disease No symptomatic ischemic heart disease Other HIV negative No active uncontrolled infection No malignancy within past 3 year except basal cell squamous cell skin cancer carcinoma situ cervix within past 2 year No prior concurrent evidence CNS psychiatric disorder require hospitalization No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy More 6 week since prior growth factor primary MDS No concurrent antiangiogenic drug ( e.g. , thalidomide ) No concurrent interleukin , interferon , antithymocyte globulin Chemotherapy See Disease Characteristics More 6 week since prior hydroxyurea primary MDS No prior chemotherapy MDS AML Prior chemotherapy solid tumor lymphoma ( result secondary MDS ) allow Endocrine therapy No concurrent steroid ( except inhalation therapy ) Radiotherapy Prior radiotherapy solid tumor lymphoma ( result secondary MDS ) allow Surgery Not specify Other More 6 week since prior immunosuppressive agent primary MDS No concurrent amifostine No concurrent cyclosporine No concurrent experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>